Tests izalontamab brengitecan versus chemotherapy in lung cancer after EGFR drug failure
Compares izalontamab brengitecan with chemotherapy in adults with EGFR-mutated lung cancer that worsened.
Plain-language title generated from the registry record
Registry title: IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Key facts
- Where
- Berlin, Chemnitz, Cologne, Donauwoerth, Esslingen am Neckar, Gauting, Hamburg, Kassel, Kiel, Stuttgart, and Ulm, GermanySee the 11 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-squamous lung cancer with an EGFR mutation, whose disease grew during treatment with a 3rd-generation EGFR-TKI.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Non-squamous non-small cell lung cancer that cannot be treated with the aim of removing all of the disease. The disease grew on the most recent EGFR-TKI treatment.
- Earlier treatment
- Must have had a 3rd-generation EGFR-TKI (such as osimertinib, furmonertinib, lazertinib) as the most recent line of treatment, alone or combined. Must be able to have platinum-based chemotherapy (cisplatin or carboplatin with pemetrexed).
- Biomarker or test result
- A documented EGFR mutation (exon 19 deletion or L858R mutation).
Main reasons for not taking part
- Not enough organ function or bone marrow reserve
- Cancer spread to the lining of the brain and spinal cord (leptomeningeal metastases)
- Spinal cord compression
- Poorly controlled medical conditions affecting the whole body
Read by machine on 9 November 2026.
Where in Germany
- Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbHBerlin, GermanyNot yet recruiting
- Klinikum Chemnitz gGmbHChemnitz, GermanyNot yet recruiting
- Kliniken der Stadt Koeln gGmbHCologne, GermanyNot yet recruiting
- Onkologie Donauwoerth (MVZ) GmbHDonauwoerth, GermanyNot yet recruiting
- Klinikum Esslingen GmbHEsslingen am Neckar, GermanyNot yet recruiting
- Asklepios Klinik Gauting GmbHGauting, GermanyNot yet recruiting
- Asklepios Kliniken Hamburg GmbHHamburg, GermanyNot yet recruiting
- Klinikum Kassel GmbHKassel, GermanyNot yet recruiting
- Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyNot yet recruiting
- Robert Bosch Gesellschaft fuer medizinische Forschung mbHStuttgart, GermanyNot yet recruiting
- Universitaetsklinikum Ulm AoRUlm, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb Services Unlimited Company
- Trial code
- EU 2025-521908-22-00
- Record updated
- 13 October 2026
- Original description
Phase 3: To compare the progression-free survival of iza-bren at RP3D vs platinum-based chemotherapy in participants with advanced EGFRmt NSCLC cancer and disease progression after any 3rd generation TKIsRead full original descriptionShow less
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
Phase 3: To compare the progression-free survival of iza-bren at RP3D vs platinum-based chemotherapy in participants with advanced EGFRmt NSCLC cancer and disease progression after any 3rd generation TKIs
Inclusion: Non-squamous NSCLC, not amenable to treatment in curative intent; Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation); Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting; Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Exclusion: Poorly controlled systemic medical conditions; Inadequate organ function and/or bone marrow reserve; Leptomeningeal metastases or spinal cord compression.